P/E ratio for Bellerophon Therapeutics (BLPH)
P/E ratio as of May 2024 (TTM): -0.0424
According to Bellerophon Therapeutics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.0423967. At the end of 2022 the company had a P/E ratio of -0.4327.
P/E ratio history for Bellerophon Therapeutics from 2015 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -0.4327 | -73.76% |
| 2021 | -1.65 | -18.67% |
| 2020 | -2.03 | 12.76% |
| 2019 | -1.80 | -110.92% |
| 2018 | 16.5 | -980.36% |
| 2017 | -1.87 | 475.25% |
| 2016 | -0.3250 | -66.13% |
| 2015 | -0.9596 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Abbott Laboratories ABT | 35.8 | -84,449.49% | 🇺🇸 USA |
 Baxter BAX | 7.88 | -18,683.78% | 🇺🇸 USA |
 Lantheus Holdings LNTH | 44.0 | -103,989.69% | 🇺🇸 USA |
 Abeona Therapeutics
ABEO | -1.30 | 2,970.50% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.